Abstracts tagged "Autoantibody(ies)"

Abstract Number: 0927 • ACR Convergence 2023
A Complex Interplay Among Gut Lachnoclostidium, HLA Haplotype DRB1*07:01, and the TNF Superfamily in Anti-Ro+ Women with a Spectrum of Preclinical and Clinical Autoimmunity Whose Children Have Neonatal Lupus
Robert Clancy¹, Caroline Izmirly¹, Miranda Marion², Nicola Fraser¹, Joel Guthridge³, Timothy Howard², Peter Izmirly⁴, Mala Masson⁵, Jill Buyon¹, Judith James³ and Carl Langefeld⁶, ¹NYU Grossman School of Medicine, New York, NY, ²Wake Forest University, Winston-Salem, NC, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴New York University School of Medicine, New York, NY, ⁵New York University, New York, NY, ⁶Wake Forest University School of Medicine, Winston-Salem, NC
Background/Purpose: Mothers of children with neonatal lupus (NL) are often clinically asymptomatic or have insufficient criteria for a formal rheumatologic diagnosis, despite having high titers…
Abstract Number: 1458 • ACR Convergence 2023
Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity
Kittikorn Wangriatisak¹, Francesca Faustini², Charlotte de Vries³, Ravi Kumar Sharma⁴, Caroline Grönwall⁵, Prapaporn Pisitkun⁶, Patchanee Chootong⁷, Vivianne Malmström⁵ and Iva Gunnarsson⁸, ¹Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Thailand ; Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁵Karolinska Institutet, Stockholm, Sweden, ⁶Division of Allergy Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bankok, Thailand, ⁷Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand, ⁸Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna, Sweden; Medicine Unit Dermatology, Gastroenterology, Rheumatology; unit of Rheumatology, Karolinska University Hospital Solna, Sweden, Stockholm, Sweden
Background/Purpose: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE), which is characterized by abnormal B-cell activation and their…
Abstract Number: 1931 • ACR Convergence 2023
Anti-Ku Antibodies: A Case Series
Raquel Ugena García¹, Cristina Calomarde Gomez¹, Joan Climent² and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Anti-Ku antibodies (Abs) were initially described in patients with polymyositis and scleroderma. Subsequently, an association has been demonstrated with other systemic autoimmune diseases (SADs),…
Abstract Number: 2434 • ACR Convergence 2023
Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response
Mikhail Volkov, Arieke Kampstra, Karin van Schie, Joanneke Kwekkeboom, Arnoud de Ru, Peter van Veelen, Thomas Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Gut-residing bacteria, such as E.coli, can acetylate their proteome under conditions of amine starvation. It is postulated that the (gut) microbiome is involved in…
Abstract Number: 0105 • ACR Convergence 2023
Characterization of B-Cell Subsets in Antiphospholipid Syndrome Patients: Implications for Disease Phenotype and Pathogenesis
Yin Long¹, Jiuliang zhao², Mengtao Li² and Xiaofeng Zeng², ¹Peking Union Medical College Hospital Department of Rheumatology and Clinical Immunology, Beijing, China, ²Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Background/Purpose: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by the presence of pathogenic autoantibodies. The key immune cell subsets change in PAPS patients…
Abstract Number: 0603 • ACR Convergence 2023
Antiphospholipid Antibodies as Potential Predictors of Disease Severity and Poor Prognosis in Systemic Lupus Erythematosus Associated Thrombocytopeinia
Mehret Birru Talabi¹, Bonnie Bermas², Irene Blanco³, Ashira Blazer⁴, Megan Clowse⁵, Cuoghi Edens⁶, Leslie Pierce⁷, Catherine Wright¹ and Rosalind Ramsey-Goldman³, ¹University of Pittsburgh, Pittsburgh, PA, ²UT Southwestern, Dallas, TX, ³Northwestern University, Chicago, IL, ⁴Hospital for Special Surgery, New York, NY, ⁵Duke University, Chapel Hill, NC, ⁶University of Chicago, Chicago, IL, ⁷University of Pittsburgh, Raleigh, NC
Background/Purpose: Thrombocytopenia (TP) is a common hematologic abnormality in systemic lupus erythematosus (SLE). Severe thrombocytopenia is correlated with disease activity and a worse prognosis of…
Abstract Number: 0933 • ACR Convergence 2023
The ‘Sweet’ in Lupus – IgG Glycosylation in Lupus Nephritis
Rhea Bhargava¹, Rohit Upadhyay², Scott Wenderfer³, Jing Chen² and George Tsokos⁴, ¹Tulane University, New Orleans, LA, ²Tulane University School of Medicine, New Orleans, LA, ³University of British Columbia, Vancouver, BC, Canada, ⁴Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Lupus nephritis (LN) occurs in 50% of patients with systemic lupus erythematosus (SLE) for which we lack biomarkers, and an understanding of its pathogenesis.…
Abstract Number: 1467 • ACR Convergence 2023
Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mariana Gonzalez-Trevino¹, Jeffrey Yang², Larry J. Prokop³, Gabriel Figueroa-Parra¹ and Ali Duarte-Garcia⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Internal Medicine, Mayo Clinic, Rochester, MN, ³Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is one of the most devastating complications of SLE. The exact pathogenesis leading to DAH in SLE is not well…
Abstract Number: 1944 • ACR Convergence 2023
Characterization of Interstitial Pneumonia with Autoimmune Features (IPAF) in a National Referral Centre
Arturo Llobell¹, Belén Atienza-Mateo², David Iturbe-Fernández³, Victor Mora-Cuesta³, Marcos Lopez-Hoyos⁴, Jose Cifrian⁵ and Ricardo Blanco⁶, ¹Parc Tauli University Hospital, Barcelona, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital, Santander, Spain, ⁴Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain, ⁵Immunopathology Group, Marqués de Valdecilla University Hospital-IDIVAL; Department of Pneumology, Marqués de Valdecilla University Hospital; School of Medicine, Cantabria University, Santander, Spain, ⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) comprises a wide range of disorders categorized by clinical, radiographic and pathologic findings that is closely associated with autoimmune connective…
Abstract Number: 2465 • ACR Convergence 2023
Clonally Expanded B Cells in Anti-Histidyl-tRNA Synthetase Syndrome Patients Exhibit an Autoreactive-Prone Memory Phenotype and Bind Jo-1 Autoantigen
Lindsay Bass¹, Dena Liu¹, Alberto Cisneros², Jennifer Young-Glazer², Leslie Crofford³, Erin Wilfong² and Rachel Bonami², ¹Vanderbilt University, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, TN, ³Vanderbilt University Medical Center, Melbourne, AR
Background/Purpose: Anti-histidyl-tRNA synthetase syndrome (Jo-1 ARS) is defined by the presence of autoantibodies against histidyl tRNA synthetase (Jo-1). Clinically, Jo-1 ARS can involve multiple tissues…
Abstract Number: 0106 • ACR Convergence 2023
Positive Antiphospholipid Antibodies Are Associated with a Higher Risk of Cerebral Microbleeds
Junna Ye¹, Yijun You², Zhuochao Zhou², Fan wang², Jingyi Wu² and Chengde Yang², ¹Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China, ²Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background/Purpose: Persistent presence of antiphospholipid antibodies (aPLs) are important thrombosis-related laboratory parameters, as well as an indication of anticoagulation use which usually cause higher bleeding…
Abstract Number: 0608 • ACR Convergence 2023
Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post-hoc Analysis from a Phase 2 Study
Anca Askanase¹, David D'Cruz², Kenneth Kalunian³, Joan Merrill⁴, Sandra Navarra⁵, Clélia Cahuzac⁶, Peter Cornelisse⁶, Daniel Strasser⁶, Luba Trokan⁷ and Ouali Berkani⁸, ¹Columbia University Medical Center, New York, NY, ²Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ³University of California San Diego, La Jolla, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, ⁶Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, ⁷Idorsia Pharmaceuticals Ltd. at time of data generation, Allschwil, Switzerland, ⁸IDORSIA, Allschwil, Switzerland
Background/Purpose: Cenerimod is an orally active, selective sphingosine 1-phosphate (S1P) 1 receptor modulator under investigation for the treatment of systemic lupus erythematosus (SLE). In the…
Abstract Number: 0946 • ACR Convergence 2023
Immunoglobulins G Purified from Systemic Sclerosis Patients Influence Cytoplasmic and Nuclear Proteins Profile in Dermal Fibroblasts
Aurélien Chepy¹, Marie Duhamel², Solange Vivier¹, Clément Chauvet¹, Lucile Guilbert³, Eric Hachulla⁴, Sylvain Dubucquoi¹, David Launay¹, Michel Salzet² and Vincent Sobanski¹, ¹Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France, ²Univ. Lille, Inserm, CHU Lille, U1192 - Protéomique Réponse Inflammatoire Spectrométrie de Masse - PRISM, Lille, France, ³CHU Lille, Institut d’Immunologie, Lille, France, ⁴CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France
Background/Purpose: Autoantibodies (Aab) are frequent in systemic sclerosis (SSc). While recognized as potent biomarkers, their pathogenic role is unclear. Recently, we showed that immunoglobulins G…
Abstract Number: 1475 • ACR Convergence 2023
Retrospective Study of Obesity on Clinical and Immunological Features in Systemic Lupus Erythematosus Using AI Software Deep 6 and EPIC Slicer Dicer
Shivani Shah¹, chandana keshavamurthy¹, Samantha Ahrens¹, Douglas Reeves¹, William Davis¹, Robert Quinet¹, Jerald Zakam¹, Samina Hayat², Teresa Leeth², Sarwat Umer³, Sulman Hasan², Maria Latsis², Xin Zhang¹ and Gitanjali Lobo⁴, ¹Ochsner Health, New Orleans, LA, ²Louisiana State University, Shreveport, LA, ³LSU Health Shreveport, Shreveport, LA, ⁴Ochsner Clinic Foundation, Baton Rouge, LA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by autoantibodies and systemic inflammation, affecting multiple organs especially kidney. Environmental factors, genetic predisposition,…
Abstract Number: 1949 • ACR Convergence 2023
Relapse of Rapidly Progressive Interstitial Lung Disease in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibody-Positive Dermatomyositis
Noriko Sasaki, Toshiki Ohisa, Akira Ishii, Mai Sugiyama, Yuichiro Ota, Chiho Yamada and Shinji Sato, Tokai university School of Medicine, Isehara, Japan
Background/Purpose: Autoantibodies to Melanoma Differentiation-Associated Gene 5 (MDA5) are found specifically in patients with dermatomyositis (DM). Their presence is closely associated with rapidly progressive interstitial…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].